Amylin Sees Symlin Playing “Foundational Role” In Obesity Program
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO-to-be Bradbury outlines plans for several obesity studies of pramlintide in combination with marketed and investigational products.
You may also be interested in...
Vivus Poised To Enter Phase III With Obesity Candidate Qnexa
Firm touts safety advantage of experimental phentermine/topiramate combination therapy.
Vivus Poised To Enter Phase III With Obesity Candidate Qnexa
Firm touts safety advantage of experimental phentermine/topiramate combination therapy.
Psylin Neurosciences Will Focus On Development of Psychiatric Drugs
New company is formed out of a joint venture between Amylin and PsychoGenics.